<div id="readability-page-1"><ul><li>How Does D-Wave Stack Up Against Quantum Competitors?</li></ul><p>AstraZeneca, Eli Lilly and Company, Novo Nordisk A/S, AbbVie,  and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies whose primary business is researching, developing, manufacturing, and selling prescription drugs and related therapies. For investors, these stocks are often evaluated based on drug pipelines, regulatory approvals, patent protection, and commercialization prospects, and they can show higher volatility due to trial outcomes, approval decisions, and patent expirations. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><h2>AstraZeneca (AZN)</h2><p>AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.</p><ul><li>Tempus AI Stock: Time to Double Down or Cut and Run?</li></ul><p>Read Our Latest Research Report on AZN</p><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Novo Nordisk A/S (NVO)</h2><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><p>Read Our Latest Research Report on NVO</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><p>Read Our Latest Research Report on ABBV</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><p>Read Our Latest Research Report on PFE</p><h2>Further Reading</h2><ul><li>MarketBeat's Top Five Stocks to Own in January 2026</li><li>Big Risk, Potentially Bigger Return For These 3 Leveraged ETF's</li><li>The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway)</li><li>Spotify’s Price Hike: Why Subscribers Will Pay Up</li><li>The Cloud Computing ETF Every Growth Investor Should Consider</li><li>3 Stocks to Avoid as Software Sector Stumbles</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AstraZeneca Right Now?</h2><p>Before you consider AstraZeneca, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.</p><p>While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>AstraZeneca, Eli Lilly, Novo Nordisk, AbbVie, and Pfizer are highlighted as top pharmaceutical stocks to watch today, according to MarketBeat. These companies are involved in the research, development, and sale of prescription drugs, with their stocks evaluated based on drug pipelines and regulatory approvals. AstraZeneca focuses on various therapeutic areas, while Eli Lilly specializes in diabetes and obesity treatments. Novo Nordisk operates in diabetes care, AbbVie offers treatments for autoimmune diseases, and Pfizer provides a range of biopharmaceutical products, including COVID-19 vaccines.</p>

Top Pharmaceutical Stocks To Follow Today - January 18th